FilingSEC EDGAR6-K
Biodexa Completes Enrollment of 100 Patients in FAP Phase 3 Trial
· SEC accepted
StagePhase 3
Filing content
Biodexa Pharmaceuticals has enrolled 100 patients in its Serenta Phase 3 trial for FAP, with expectations that upcoming analysis milestones will occur sooner than anticipated.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…